Two thoughts:
1.) The extra cash. May come from prepayments for MUSE. Perhaps those countries that will not launch until later want to lock in a fixed price now before Germany launch could drive up the wholesale price. Since VVUS recognizes revenue only when product shipped, this would not be accounted for as revenue but as a short term "loan". And would not be revealed in the P&L statement. If it were milestone payment that WOULD show up in the revenue statement.
This would cause an increase in current assets and an equal increase in current liabilities, which seems to be the case in my brief perusal of the balance sheet. Other comments welcome, I had a late meeting last night and have not looked closely at the financials.
2.) The AUA meeting in Dallas on May 4-5 is just two weeks away, from all indications there will be a lot more positives for MUSE, and probable negatives for Brand X to come out of that.
Just yesterday I talked to a patient that I prescribed the V pill to. His wife was upset with him for getting it and not telling her, she is worried about side effects and the danger. I told him it was safe for most people, but also informed him of an alternative Rx, MUSE, which of course he had never heard of.
Potential is still there to sell this big in the US with a marketing force IMHO.
I have looked at the (weekly interval) TA and it is positive, so I won't like the CC-related sell off I expect to see this AM, but I'm not selling, and I think the big blocks won't be selling either. iqc.com
Just a guess, I could be wrong.
Zebra |
